365 related articles for article (PubMed ID: 16187338)
1. In vitro galactosylation of human IgG at 1 kg scale using recombinant galactosyltransferase.
Warnock D; Bai X; Autote K; Gonzales J; Kinealy K; Yan B; Qian J; Stevenson T; Zopf D; Bayer RJ
Biotechnol Bioeng; 2005 Dec; 92(7):831-42. PubMed ID: 16187338
[TBL] [Abstract][Full Text] [Related]
2. Contrasting glycosylation profiles between Fab and Fc of a human IgG protein studied by electrospray ionization mass spectrometry.
Mimura Y; Ashton PR; Takahashi N; Harvey DJ; Jefferis R
J Immunol Methods; 2007 Sep; 326(1-2):116-26. PubMed ID: 17714731
[TBL] [Abstract][Full Text] [Related]
3. Site-specific N-glycosylation of chicken serum IgG.
Suzuki N; Lee YC
Glycobiology; 2004 Mar; 14(3):275-92. PubMed ID: 14693911
[TBL] [Abstract][Full Text] [Related]
4. Assessing Fc glycan heterogeneity of therapeutic recombinant monoclonal antibodies using NP-HPLC.
Raju TS
Methods Mol Biol; 2013; 988():169-80. PubMed ID: 23475719
[TBL] [Abstract][Full Text] [Related]
5. Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides.
Wormald MR; Rudd PM; Harvey DJ; Chang SC; Scragg IG; Dwek RA
Biochemistry; 1997 Feb; 36(6):1370-80. PubMed ID: 9063885
[TBL] [Abstract][Full Text] [Related]
6. Production and molecular characterization of clinical phase i anti-melanoma mouse IgG3 monoclonal antibody R24.
Kemminer SE; Conradt HS; Nimtz M; Sagi D; Peter-Katalinić J; Diekmann O; Drmić I; Müthing J
Biotechnol Prog; 2001; 17(5):809-21. PubMed ID: 11587568
[TBL] [Abstract][Full Text] [Related]
7. Mass spectrometry and HPLC for carbohydrate analysis.
Siemiiatkoski J; Lyubarskaya Y
Dev Biol (Basel); 2005; 122():69-74. PubMed ID: 16375251
[TBL] [Abstract][Full Text] [Related]
8. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
9. Restricted processing of CD16a/Fc γ receptor IIIa
Patel KR; Roberts JT; Subedi GP; Barb AW
J Biol Chem; 2018 Mar; 293(10):3477-3489. PubMed ID: 29330305
[TBL] [Abstract][Full Text] [Related]
10. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro.
Hodoniczky J; Zheng YZ; James DC
Biotechnol Prog; 2005; 21(6):1644-52. PubMed ID: 16321047
[TBL] [Abstract][Full Text] [Related]
11. Effect of posttranslational modifications on the thermal stability of a recombinant monoclonal antibody.
Liu H; Bulseco GG; Sun J
Immunol Lett; 2006 Aug; 106(2):144-53. PubMed ID: 16831470
[TBL] [Abstract][Full Text] [Related]
12. The effect of Fc glycan forms on human IgG2 antibody clearance in humans.
Chen X; Liu YD; Flynn GC
Glycobiology; 2009 Mar; 19(3):240-9. PubMed ID: 18974198
[TBL] [Abstract][Full Text] [Related]
13. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality.
Scallon BJ; Tam SH; McCarthy SG; Cai AN; Raju TS
Mol Immunol; 2007 Mar; 44(7):1524-34. PubMed ID: 17045339
[TBL] [Abstract][Full Text] [Related]
14. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans.
Goetze AM; Liu YD; Zhang Z; Shah B; Lee E; Bondarenko PV; Flynn GC
Glycobiology; 2011 Jul; 21(7):949-59. PubMed ID: 21421994
[TBL] [Abstract][Full Text] [Related]
15. Metabolic control of recombinant monoclonal antibody N-glycosylation in GS-NS0 cells.
Hills AE; Patel A; Boyd P; James DC
Biotechnol Bioeng; 2001 Oct; 75(2):239-51. PubMed ID: 11536148
[TBL] [Abstract][Full Text] [Related]
16. Biochemical characterization of rhEpo-Fc fusion protein expressed in CHO cells.
Schriebl K; Trummer E; Lattenmayer C; Weik R; Kunert R; Müller D; Katinger H; Vorauer-Uhl K
Protein Expr Purif; 2006 Oct; 49(2):265-75. PubMed ID: 16861003
[TBL] [Abstract][Full Text] [Related]
17. Terminal sugars of Fc glycans influence antibody effector functions of IgGs.
Raju TS
Curr Opin Immunol; 2008 Aug; 20(4):471-8. PubMed ID: 18606225
[TBL] [Abstract][Full Text] [Related]
18. Highly sensitive HPLC analysis and biophysical characterization of N-glycans of IgG-Fc domain in comparison between CHO and 293 cells using FcγRIIIa ligand.
Kosuge H; Nagatoishi S; Kiyoshi M; Ishii-Watabe A; Tanaka T; Terao Y; Oe S; Ide T; Tsumoto K
Biotechnol Prog; 2020 Nov; 36(6):e3016. PubMed ID: 32390308
[TBL] [Abstract][Full Text] [Related]
19. Quantitative glycan profiling of normal human plasma derived immunoglobulin and its fragments Fab and Fc.
Anumula KR
J Immunol Methods; 2012 Aug; 382(1-2):167-76. PubMed ID: 22683540
[TBL] [Abstract][Full Text] [Related]
20. Fc glycans terminated with N-acetylglucosamine residues increase antibody resistance to papain.
Raju TS; Scallon B
Biotechnol Prog; 2007; 23(4):964-71. PubMed ID: 17571902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
